The shortage of life-sustaining drugs for cancer, diabetes, and ADHD that has plagued hospitals and patients for years has now reached its peak with 323 medicines officially in short supply.
The Biosimilars Council released a new analysis by IQVIA that reveals a PBM strategy to protect $2 billion in profits by “strangling” the biosimilar market and preventing savings for patients.